Tufts CSDD Releases January/February 2022 Impact Report
Tufts CSDD has released the latest version of its bi-monthly Impact Report. In this January/February 2022 edition, the focus is on an issue that has plagued the pharmaceutical industry for years: the incidence of protocol deviations and amendments in clinical trials. While these hurdles are both at new highs across all phases, they have been steadily increasing since the start of the COVID-19 pandemic.
From the results a new Tufts CSDD analysis conducted in 2020, some of the highlights in the report are:
- Actual timelines for protocols with three or more substantial amendments are nearly three weeks longer than planned treatment durations.
- In a typical Phase III trial, 119 protocol deviations, on average, are implemented, involving approximately one-third of all patients participating in that trial.
The full report is available for purchase here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
